Cargando…

Duplex Sequencing Uncovers Recurrent Low-frequency Cancer-associated Mutations in Infant and Childhood KMT2A-rearranged Acute Leukemia

Infant acute lymphoblastic leukemia (ALL) with KMT2A-gene rearrangements (KMT2A-r) have few mutations and a poor prognosis. To uncover mutations that are below the detection of standard next-generation sequencing (NGS), a combination of targeted duplex sequencing and NGS was applied on 20 infants an...

Descripción completa

Detalles Bibliográficos
Autores principales: Pilheden, Mattias, Ahlgren, Louise, Hyrenius-Wittsten, Axel, Gonzalez-Pena, Veronica, Sturesson, Helena, Hansen Marquart, Hanne Vibeke, Lausen, Birgitte, Castor, Anders, Pronk, Cornelis Jan, Barbany, Gisela, Pokrovskaja Tamm, Katja, Fogelstrand, Linda, Lohi, Olli, Norén-Nyström, Ulrika, Asklin, Johanna, Chen, Yilun, Song, Guangchun, Walsh, Michael, Ma, Jing, Zhang, Jinghui, Saal, Lao H., Gawad, Charles, Hagström-Andersson, Anna K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9529062/
https://www.ncbi.nlm.nih.gov/pubmed/36204688
http://dx.doi.org/10.1097/HS9.0000000000000785
Descripción
Sumario:Infant acute lymphoblastic leukemia (ALL) with KMT2A-gene rearrangements (KMT2A-r) have few mutations and a poor prognosis. To uncover mutations that are below the detection of standard next-generation sequencing (NGS), a combination of targeted duplex sequencing and NGS was applied on 20 infants and 7 children with KMT2A-r ALL, 5 longitudinal and 6 paired relapse samples. Of identified nonsynonymous mutations, 87 had been previously implicated in cancer and targeted genes recurrently altered in KMT2A-r leukemia and included mutations in KRAS, NRAS, FLT3, TP53, PIK3CA, PAX5, PIK3R1, and PTPN11, with infants having fewer such mutations. Of identified cancer-associated mutations, 62% were below the resolution of standard NGS. Only 33 of 87 mutations exceeded 2% of cellular prevalence and most-targeted PI3K/RAS genes (31/33) and typically KRAS/NRAS. Five patients only had low-frequency PI3K/RAS mutations without a higher-frequency signaling mutation. Further, drug-resistant clones with FLT3(D835H) or NRAS(G13D/G12S) mutations that comprised only 0.06% to 0.34% of diagnostic cells, expanded at relapse. Finally, in longitudinal samples, the relapse clone persisted as a minor subclone from diagnosis and through treatment before expanding during the last month of disease. Together, we demonstrate that infant and childhood KMT2A-r ALL harbor low-frequency cancer-associated mutations, implying a vast subclonal genetic landscape.